

---

---

---

---

---

---

## The Annual General Meeting of Hansa Medical has been rescheduled to May 6, 2013

The Board of Hansa Medical has resolved to reschedule the Annual General Meeting (AGM) from May 7 to **May 6, 2013 at 17:00 in Hörsalen at Scheelevägen 22 in Lund**. A separate Notice of the AGM will be published at the latest on April 2, 2013.

**For further information, please contact:**

Emanuel Björne, CEO Hansa Medical AB

Mobile: +46 707 17 54 77

E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)

[www.hansamedical.com](http://www.hansamedical.com)

---

### ABOUT HANSA MEDICAL

Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. Presently, the company is focusing on three development projects; IdeS, EndoS and HMD-301. New development projects and product candidates generated out of cooperation with medical academic research are continuously evaluated. Major shareholders: Bo Håkansson via Farstorps Gärd AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company's Certified Adviser.

### Hansa Medical AB

P.O. Box 785  
SE-220 07 Lund  
Telefon +46 46 16 56 70  
Fax +46 46 12 77 75  
[info@hansamedical.com](mailto:info@hansamedical.com)  
[www.hansamedical.com](http://www.hansamedical.com)

### Visiting address:

Scheelevägen 22  
Lund, Sweden